Cargando…

Effects of body composition and liver function after long-term pemafibrate treatment on dyslipidemia-associated non-alcoholic fatty liver disease

AIM OF THE STUDY: Owing to the association between non-alcoholic fatty liver disease (NAFLD) and dyslipidemia, there is a need for new treatment strategies to manage both conditions concomitantly. Our aim in this study was to evaluate the effectiveness of pemafibrate in alleviating dyslipidemia-asso...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ishikawa, Toru, Terai, Nanako, Igarashi, Takanori, Yamazaki, Shun, Kobayashi, Takamasa, Sato, Toshifumi, Iwanaga, Akito, Sano, Tomoe, Yokoyama, Junji, Honma, Terasu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2023
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10369653/ https://www.ncbi.nlm.nih.gov/pubmed/37502434 http://dx.doi.org/10.5114/ceh.2023.127813

Ejemplares similares

Comparison of Ablation Volume Between Emprint(®) and Mimapro(®) Systems for Hepatocellular Carcinoma –A Preliminary Study
por: Ishikawa, Toru, et al.
Publicado: (2023)

Clinical Usefulness of Transjugular Liver Biopsy in Patients With Hematological Diseases With Liver Dysfunction
por: Ishikawa, Toru, et al.
Publicado: (2021)

Analysis of predictors after partial splenic embolization for thrombocytopenia with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2022)

Risk factors for difficult endoscopic hemostasis for colonic diverticular bleeding and efficacy and safety of transcatheter arterial embolization
por: Sano, Tomoe, et al.
Publicado: (2023)

Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis
por: Ishikawa, Toru, et al.
Publicado: (2017)

Comparison of the efficacy of self-expandable metallic stents in colorectal obstructions caused by extracolonic malignancy and colorectal cancer
por: Sano, Tomoe, et al.
Publicado: (2021)

Eosinophilic esophagitis in Japanese patients: A mild and slow-progressing disorder
por: Sato, Hiroki, et al.
Publicado: (2018)

Clinical efficacy of the highly sensitive hepatitis C virus RNA quantitative assay in patients with relapse following interferon-based therapy with second-generation direct-acting antivirals
por: ISHIKAWA, TORU, et al.
Publicado: (2016)

Telaprevir-based triple therapy following partial splenic arterial embolization for chronic hepatitis C with thrombocytopenia can reduce carcinogenesis and improve hepatic function reserve
por: ISHIKAWA, TORU, et al.
Publicado: (2015)

Improved survival with double platinum therapy transcatheter arterial infusion using cisplatin and transcatheter arterial chemoembolization using miriplatin for BCLC-B hepatocellular carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2016)

Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy
por: Ishikawa, Toru, et al.
Publicado: (2020)

Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma
por: Imai, Michitaka, et al.
Publicado: (2020)

Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment
por: Ishikawa, Toru, et al.
Publicado: (2018)

Cone beam versus conventional computed tomography angiography volume measurement in partial splenic embolization
por: Ishikawa, Toru, et al.
Publicado: (2019)

Efficacy and safety of repeated use of lusutrombopag prior to radiofrequency ablation in patients with recurrent hepatocellular carcinoma and thrombocytopenia
por: Ishikawa, Toru, et al.
Publicado: (2019)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Hemorrhagic Gastric Metastasis from Hepatocellular Carcinoma Successfully Treated Using Coil Embolization of the Left Gastric Artery
por: Imai, Michitaka, et al.
Publicado: (2019)

Effect of pemafibrate on liver enzymes and shear wave velocity in non-alcoholic fatty liver disease patients
por: Sugimoto, Ryosuke, et al.
Publicado: (2023)

Rapid Onset of Weight Gain and Liver Dysfunction Successfully Treated With Nutrition and Exercise
por: Kamimura, Hiroteru, et al.
Publicado: (2021)

Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis
por: Ida, Satoshi, et al.
Publicado: (2019)

Predictive Factor of Local Recurrence after Balloon-Occluded TACE with Miriplatin (MPT) in Hepatocellular Carcinoma
por: Ishikawa, Toru, et al.
Publicado: (2014)

Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2019)

Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage
por: Nomoto, Hiroshi, et al.
Publicado: (2023)

Ascending Colon Varices Due to Left-sided Portal Hypertension
por: Ishikawa, Toru, et al.
Publicado: (2021)

Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease
por: Shinozaki, Satoshi, et al.
Publicado: (2020)

Combination Therapy Using Pemafibrate and Dapagliflozin for Metabolic Dysfunction-associated Fatty Liver Disease
por: Imamura, Teruhiko, et al.
Publicado: (2022)

FRI096 Efficacy Of Pemafibrate In Patients With Dyslipidemia: A Systematic Review And Meta - Analysis Of Randomized Controlled Trials
por: Caroline Cristine, Almeida Balieiro, et al.
Publicado: (2023)

Higher Responsiveness for Women, High Transaminase Levels, and Fat Percentage to Pemafibrate Treatment for NAFLD
por: Iwadare, Takanobu, et al.
Publicado: (2022)

Molecular Mechanisms and Treatment of Sarcopenia in Liver Disease: A Review of Current Knowledge
por: Kamimura, Hiroteru, et al.
Publicado: (2021)

Pemafibrate, a New Selective PPARα Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases
por: Yamashita, Shizuya, et al.
Publicado: (2020)

Effect of Pemafibrate on Hemorheology in Patients with Hypertriglyceridemia and Aggravated Blood Fluidity Associated with Type 2 Diabetes or Metabolic Syndrome
por: Iwakura, Tomohiro, et al.
Publicado: (2023)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis
por: Sakamaki, Akira, et al.
Publicado: (2020)

Pemafibrate therapy for non-alcoholic fatty liver disease is more effective in lean patients than obese patients
por: Shinozaki, Satoshi, et al.
Publicado: (2022)

Comparison of the relationships of alcoholic and nonalcoholic fatty liver with hypertension, diabetes mellitus, and dyslipidemia
por: Toshikuni, Nobuyuki, et al.
Publicado: (2013)

Pemafibrate Prevents Rupture of Angiotensin II-Induced Abdominal Aortic Aneurysms
por: Amioka, Naofumi, et al.
Publicado: (2022)

Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy
por: Kanno, Kotaro, et al.
Publicado: (2022)

Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up
por: Ikeda, Suguru, et al.
Publicado: (2021)

Effect of 48‐week pemafibrate on non‐alcoholic fatty liver disease with hypertriglyceridemia, as evaluated by the FibroScan‐aspartate aminotransferase score
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

Rapid decline in visceral adipose tissue over 1 month is associated with poor prognosis in patients with unresectable pancreatic cancer
por: Nakano, Oki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nbnnfl8484ka3t0mku4o9kttp4